N
Nemdx engineers synthetic short RNA binders that directly measure interactions between proteins, cancer mutations, and bacteria using minimal sample volumes. Their assays offer ultra-high sensitivity and specificity for rapid diagnosis, precise monitoring, and efficient drug development across pharmaceutical applications. This technology provides critical insights into disease onset, progression, and therapy target engagement for personalized medical interventions.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Nemdx engineers synthetic short RNA binders that directly measure interactions between proteins, cancer mutations, and bacteria using minimal sample volumes. Their assays offer ultra-high sensitivity and specificity for rapid diagnosis, precise monitoring, and efficient drug development across pharmaceutical applications. This technology provides critical insights into disease onset, progression, and therapy target engagement for personalized medical interventions.